. Author manuscript; available in PMC: 2023 Aug 1.

Published in final edited form as: Am J Gastroenterol. 2022 Apr 13;117(8):1311–1315. doi: 10.14309/ajg.0000000000001774

Table 3.

Safety outcomes within 12 months after completing first maintenance treatment.

		Median ± Range or n (%)
First Maintenance		All patients (n=56)	Lymphocytic colitis (n=19)	Collagenous colitis (n=37)
Osteopenia^*		6 (10.7%)	3 (15.7%)	3 (8.1%)
Osteoporosis^*		3 (5.4%)	0 (0%)	3 (8.1%)
Glaucoma^*		4 (7.1%)	1 (5.3%)	3 (8.1%)
Cataracts^*		6 (10.7%)	2 (10.5%)	4 (10.8%)
Mood changes		6 (10.7%)	2 (10.5%)	4 (10.8%)
Hypertension	New diagnosis	0 (0%)	0 (0%)	0 (0%)
Hypertension	New or increased dose of current medication	10 (17.9%)	1 (5.3%)	9 (24.3%)
Diabetes mellitus	New diagnosis	1 (1.8%)	0 (0%)	1 (2.7%)
Diabetes mellitus	New or increased dose of current medication	1 (1.8%)	0 (0%)	1 (2.7%)

n=39 (69.6%) and n=5 (8.9%) did not have DEXA or ophthalmology exam during or within 12 months after maintenance, respectively